Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB trimmed its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 26.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,781 shares of the company’s stock after selling 12,200 shares during the period. E. Ohman J or Asset Management AB owned about 0.09% of Tarsus Pharmaceuticals worth $1,926,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of TARS. China Universal Asset Management Co. Ltd. increased its position in shares of Tarsus Pharmaceuticals by 10.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company’s stock worth $449,000 after acquiring an additional 789 shares in the last quarter. R Squared Ltd purchased a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. Franklin Resources Inc. raised its stake in Tarsus Pharmaceuticals by 9.3% during the 3rd quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after purchasing an additional 1,033 shares during the period. The Manufacturers Life Insurance Company raised its stake in Tarsus Pharmaceuticals by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,282 shares of the company’s stock valued at $905,000 after purchasing an additional 3,112 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 87.5% in the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after purchasing an additional 3,379 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 0.7 %

NASDAQ TARS opened at $54.50 on Wednesday. The company has a 50 day moving average price of $51.82 and a two-hundred day moving average price of $40.31. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.14. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Wall Street Analyst Weigh In

TARS has been the topic of several recent analyst reports. Barclays upped their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. The Goldman Sachs Group upped their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Finally, Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.